Evidence map›Paper›PMID 31300732›Full record

ArticleScientific reports2019

Evaluation of in silico designed inhibitors targeting MelF (Rv1936) against Mycobacterium marinum within macrophages.

Renu Dharra, V S Radhakrishnan, Tulika Prasad, Zoozeal Thakur, Jeffrey D Cirillo, Abhishek Sheoran, Amit K Pandey, Mahesh Kulharia, Promod K Mehta

Abstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Renu DharraCentre for Biotechnology, Maharshi Dayanand University (MDU), Rohtak, 124001, India.ORCID http://orcid.org/0000-0003-0734-4255
V S RadhakrishnanAdvanced Instrumentation Research and Facility (AIRF) and Special Center for Nano Science (SCNS), Jawaharlal Nehru University (JNU), New Delhi, 110067, India.
Tulika PrasadAdvanced Instrumentation Research and Facility (AIRF) and Special Center for Nano Science (SCNS), Jawaharlal Nehru University (JNU), New Delhi, 110067, India.
Zoozeal ThakurCentre for Biotechnology, Maharshi Dayanand University (MDU), Rohtak, 124001, India.
Jeffrey D CirilloDepartment of Microbial and Molecular Pathogenesis, Texas A&M Health Science Center, College Station, TX, 77843-1114, USA.ORCID http://orcid.org/0000-0003-3058-2702
Abhishek SheoranDepartment of Statistics, Ramanujan College, University of Delhi, New Delhi, 110019, India.
Amit K PandeyTranslational Health Science and Technology Institute (THSTI), Faridabad, 121001, India.
Mahesh KulhariaSchool of Basic and Applied Science, Central University of Punjab, Bathinda, 151001, India.
Promod K MehtaCentre for Biotechnology, Maharshi Dayanand University (MDU), Rohtak, 124001, India. pkmehta3@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We recently identified inhibitors targeting Mycobacterium marinum MelF (Rv1936) by in silico analysis, which exhibited bacteriostatic/bactericidal activity against M. marinum and M. tuberculosis in vitro. Herein, we evaluated the effect of best four inhibitors (# 5175552, # 6513745, # 5255829, # 9125618) obtained from the ChemBridge compound libraries, on intracellular replication and persistence of bacteria within IFN-γ activated murine RAW264.7 and human THP-1 macrophages infected with M. marinum. Inhibitors # 5175552 and # 6513745 significantly reduced (p < 0.05) the intracellular replication of bacilli during day 7 post-infection (p.i.) within RAW264.7 and THP-1 macrophages infected at multiplicity of infection (MOI) of ~1.0. These observations were substantiated by electron microscopy, which revealed the protective effect of # 5175552 in clearing the bacilli inside murine macrophages. Strikingly, # 6513745 displayed synergism with isoniazid against M. marinum in murine macrophages, whereas # 5175552 significantly suppressed (p < 0.05) the persistent bacilli during day 10-14 p.i. in infected RAW264.7 and THP-1 macrophages (MOI of ~ 0.1). Moreover, # 5175552 and # 6513745 were non-cytotoxic to host macrophages at both 1X and 5X MIC. Further validation of these inhibitors against M. tuberculosis-infected macrophages and animal models has potential for development as novel anti-tubercular agents.

Indexed as

AnimalsAntitubercular AgentsCell LineDrug SynergismHost-Pathogen InteractionsHumansInterferon-gammaIsoniazidMacrophage ActivationMacrophagesMiceMice, KnockoutMicroscopy, Electron, TransmissionMycobacterium Infections, NontuberculousMycobacterium marinumMycobacterium tuberculosisAntitubercular AgentsIFNG protein, mouseInterferon-gammaIsoniazidReactive Oxygen Species

Identifiers

PMID31300732
PMCPMC6626058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.